Daly J M, Weintraub F N, Shou J, Rosato E F, Lucia M
Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, USA.
Ann Surg. 1995 Apr;221(4):327-38. doi: 10.1097/00000658-199504000-00002.
The objective of this study was to evaluate long-term enteral nutrition support in postoperative cancer patients.
Multimodality therapy for surgical patients with upper gastrointestinal malignancies may improve survival, but often results in substantial malnutrition, immunosuppression, and morbidity. The benefits of combined inpatient and outpatient enteral feeding with standard diets or diets supplemented with arginine, RNA + omega-3 fatty acids are unclear.
Sixty adult patients with esophageal (22), gastric (16), and pancreatic (22) lesions were stratified by disease site and percent usual weight and randomized to receive supplemental or standard diet via jejunostomy beginning on the first postoperative day (goal = 25 kcal/kg/day) until hospital discharge. Patients also were randomized to receive (n = 37) or not receive (n = 23) enteral jejunostomy feedings (1000 kcal/day overnight) for the 12- to 16-week recovery and radiation/chemotherapy periods. Plasma and peripheral white blood cells were obtained for fatty acid levels and PGE2 production measurements.
Mean plasma and cellular omega 3/omega 6 fatty acid levels (percent composition) increased significantly (p < 0.05) in the arginine + omega-3 fatty acid group by postoperative day 7 (0.30 vs. 0.13) and (0.29 vs. 0.14) and continued to increase over time. Mean PGE2 production decreased significantly (p < 0.05) from 2760 to 1600 ng/10(6) cells/mL at day 7 in the arginine + omega-3 fatty acid group, whereas no significant change over time was noted in the standard group. Infectious/wound complications occurred in 10% of the supplemented group compared with 43% of the standard group (p < 0.05); mean length of hospital stay was 16 vs. 22 (p < 0.05) days, respectively. Of the patients who received postoperative chemoradiation therapy, only 1 (6%) of the 18 patients randomized to receive tube feeding did not continue, whereas 8 (61%) of the 13 patients not randomized to tube feedings required crossover to jejunostomy nutritional support.
Supplemental enteral feeding significantly increased plasma and peripheral white blood cell omega 3/omega 6 ratios and significantly decreased PGE2 production and postoperative infectious/wound complications compared with standard enteral feeding. For outpatients receiving adjuvant therapy, those initially randomized to oral feedings alone required rehospitalization more frequently, and 61% crossed over to supplemental enteral feedings.
本研究的目的是评估癌症术后患者的长期肠内营养支持。
对上消化道恶性肿瘤手术患者采用多模式治疗可能会提高生存率,但往往会导致严重的营养不良、免疫抑制和发病率。住院和门诊联合肠内喂养采用标准饮食或补充精氨酸、RNA + ω-3脂肪酸的饮食的益处尚不清楚。
60例患有食管(22例)、胃(16例)和胰腺(22例)病变的成年患者按疾病部位和通常体重百分比分层,随机分为从术后第一天开始通过空肠造口接受补充饮食或标准饮食(目标 = 25千卡/千克/天),直至出院。患者还被随机分为在12至16周的康复及放疗/化疗期间接受(n = 37)或不接受(n = 23)空肠造口肠内喂养(每晚1000千卡)。采集血浆和外周白细胞用于脂肪酸水平和PGE2生成测量。
精氨酸 + ω-3脂肪酸组术后第7天血浆和细胞ω3/ω6脂肪酸水平(百分比组成)显著升高(p < 0.05)(分别为0.30对0.13和0.29对0.14),并随时间持续升高。精氨酸 + ω-3脂肪酸组第7天平均PGE2生成量从2760显著降至1600 ng/10(6)细胞/毫升(p < 0.05),而标准组随时间无显著变化。补充组10%发生感染/伤口并发症,标准组为43%(p < 0.05);平均住院天数分别为16天和22天(p < 0.05)。在接受术后放化疗的患者中,随机接受管饲的18例患者中只有1例(6%)未继续,而未随机接受管饲的13例患者中有8例(61%)需要改用空肠造口营养支持。
与标准肠内喂养相比,补充肠内喂养显著提高了血浆和外周白细胞ω3/ω6比值,显著降低了PGE2生成及术后感染/伤口并发症。对于接受辅助治疗的门诊患者,最初随机仅接受口服喂养的患者更频繁地需要再次住院,61%改用补充肠内喂养。